nach oben

Current Hypertension Reports

Erschienen in:

01.06.2011

Stress and Its Role in Sympathetic Nervous System Activation in Hypertension and the Metabolic Syndrome

verfasst von: Elisabeth A. Lambert, Gavin W. Lambert

Erschienen in: Current Hypertension Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Stress in several guises is evident in individuals with hypertension and in those with the metabolic syndrome and may account, at least in part, for the extent and pattern of sympathetic nervous activation. Importantly, elevated activity of the sympathetic nervous system is related to the development of obesity-related illnesses including hypertension, insulin resistance, and renal, cardiac, and vascular impairment. Notably, evidence of subclinical organ damage is evident even in young, normotensive, overweight persons, thereby reinforcing the need to develop and implement effective early intervention.

Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRef

Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51:1237–46.PubMedCrossRef

Esler M, Eikelis N, Schlaich M, et al. Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress. Clin Exp Pharmacol Physiol. 2008;35:498–502.PubMedCrossRef

Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ. 2006;332:521–5.PubMedCrossRef

Esler M, Jennings G, Lambert G. Measurement of overall and cardiac norepinephrine release into plasma during cognitive challenge. Psychoneuroendocrinology. 1989;14:477–81.PubMedCrossRef

Grassi G, Seravalle G, Dell’Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538–42.PubMed

Lambert E, Straznicky N, Eikelis N, et al. Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. J Hypertens. 2007;25:1411–9.PubMedCrossRef

•• Lambert E, Sari CI, Dawood T, et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56:351–8. This article documents the association between sympathetic nervous activation and preclinical signs of end-organ damage in young, overweight, yet normotensive individuals, thereby highlighting the need for early detection and possible intervention.PubMedCrossRef

Rumantir MS, Jennings GL, Lambert GW, et al. The ‘adrenaline hypothesis’ of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens. 2000;18:717–23.PubMedCrossRef

10.

Micutkova L, Krepsova K, Sabban E, et al. Modulation of catecholamine-synthesizing enzymes in the rat heart by repeated immobilization stress. Ann NY Acad Sci. 2004;1018:424–9.PubMedCrossRef

11.

Wallin BG, Esler M, Dorward P, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol. 1992;453:45–58.PubMed

12.

Lucini D, Di Fede G, Parati G, Pagani M. Impact of chronic psychosocial stress on autonomic cardiovascular regulation in otherwise healthy subjects. Hypertension. 2005;46:1201–6.PubMedCrossRef

13.

• Flaa A, Aksnes TA, Kjeldsen SE, et al. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism. 2008;57:1422–7. Sympathetic reactivity was shown to be predictive of subsequent development of insulin resistance. PubMedCrossRef

14.

Marmot MG, Bosma H, Hemingway H, et al. Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet. 1997;350:235–9.PubMedCrossRef

15.

Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:953–62.PubMedCrossRef

16.

Bjorntorp P. Neuroendocrine abnormalities in human obesity. Metabolism. 1995;44:38–41.PubMedCrossRef

17.

Vicennati V, Pasqui F, Cavazza C, et al. Stress-related development of obesity and cortisol in women. Obesity (Silver Spring). 2009;17:1678–83.CrossRef

18.

Zhang J, Niaura R, Dyer JR, et al. Hostility and urine norepinephrine interact to predict insulin resistance: the VA normative aging study. Psychosom Med. 2006;68:718–26.PubMedCrossRef

19.

Fowler-Brown AG, Bennett GG, Goodman MS, et al. Psychosocial stress and 13-year BMI change among blacks: the Pitt county study. Obesity (Silver Spring). 2009;17:2106–9.CrossRef

20.

Block JP, He Y, Zaslavsky AM, et al. Psychosocial stress and change in weight among US adults. Am J Epidemiol. 2009;170:181–92.PubMedCrossRef

21.

van Jaarsveld CH, Fidler JA, Steptoe A, et al. Perceived stress and weight gain in adolescence: a longitudinal analysis. Obesity (Silver Spring). 2009;17:2155–61.CrossRef

22.

Zhao G, Ford ES, Dhingra S, et al. Depression and anxiety among US adults: associations with body mass index. Int J Obes (Lond). 2009;33:257–66.CrossRef

23.

Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol. 2004;24:527–31.PubMedCrossRef

24.

Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med. 2001;250:219–24.PubMedCrossRef

25.

Barton DA, Dawood T, Lambert EA, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25:2117–24.PubMedCrossRef

26.

Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9.PubMedCrossRef

27.

Vogelzangs N, Suthers K, Ferrucci L, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology. 2007;32:151–9.PubMedCrossRef

28.

Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Depressive symptoms and change in abdominal obesity in older persons. Arch Gen Psychiatry. 2008;65:1386–93.PubMedCrossRef

29.

Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry. 2007;62:1251–7.PubMedCrossRef

30.

Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159–72.PubMedCrossRef

31.

Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13:803–11.PubMedCrossRef

32.

Morris MJ, Cox HS, Lambert GW, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997;29:137–43.PubMed

33.

Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–3.PubMed

34.

Straznicky NE, Lambert EA, Lambert GW, et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998–6005.PubMedCrossRef

35.

Straznicky NE, Eikelis N, Lambert EA, Esler MD. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep. 2008;10:440–7.PubMedCrossRef

36.

Lambert E, Straznicky N, Schlaich M, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862–8.PubMedCrossRef

37.

Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533–6.PubMedCrossRef

38.

Straznicky NE, Grima MT, Eikelis N, et al: The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 2010 Dec 22 (Epub ahead of print).

39.

Mathieu P, Poirier P, Pibarot P, et al. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension. 2009;53:577–84.PubMedCrossRef

40.

Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839–47.PubMedCrossRef

41.

Wirtz PH, Ehlert U, Bartschi C, et al. Changes in plasma lipids with psychosocial stress are related to hypertension status and the norepinephrine stress response. Metabolism. 2009;58:30–7.PubMedCrossRef

42.

•• Lambert E, Dawood T, Straznicky N, et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens. 2010;28:543–50. This paper highlights the importance of psychosocial stress in influencing the pattern of sympathetic nerve firing. PubMedCrossRef

43.

Lambert E, Hotchkin E, Alvarenga M, et al. Single-unit analysis of sympathetic nervous discharges in patients with panic disorder. J Physiol. 2006;570:637–43.PubMedCrossRef

44.

Lambert E, Dawood T, Schlaich M, et al. Single-unit sympathetic discharge pattern in pathological conditions associated with elevated cardiovascular risk. Clin Exp Pharmacol Physiol. 2008;35:503–7.PubMedCrossRef

45.

Macefield VG, Rundqvist B, Sverrisdottir YB, et al. Firing properties of single muscle vasoconstrictor neurons in the sympathoexcitation associated with congestive heart failure. Circulation. 1999;100:1708–13.PubMed

46.

Shibao C, Gamboa A, Diedrich A, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49:27–33.PubMedCrossRef

47.

Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–33.PubMedCrossRef

48.

Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4.PubMedCrossRef

49.

Straznicky NE, Lambert EA, Nestel PJ, et al. Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes. 2010;59:71–9.PubMedCrossRef

Titel: Stress and Its Role in Sympathetic Nervous System Activation in Hypertension and the Metabolic Syndrome
verfasst von: Elisabeth A. Lambert
Gavin W. Lambert
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 3/2011
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-011-0186-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Renal Nerve Ablation for Resistant Hypertension

Diabetic Retinopathy and Blockade of the Renin-Angiotensin System: So What is New?

Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk?

New Approaches to Quantifying Sympathetic Nerve Activity

Neural Mechanisms of Angiotensin II–Salt Hypertension: Implications for Therapies Targeting Neural Control of the Splanchnic Circulation